Navigation Links
Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation
Date:7/29/2008

first time by Robert C. Green, MD, MPH, of Boston University School of Medicine. Tarenflurbil is classified as a selective amyloid lowering agent, which was shown in nonclinical studies to modulate gamma secretase activity. The drug was in trials in people with mild Alzheimer's to determine if its ability to lower the amount of toxic beta-amyloid would slow or stop the course of the disease.

In the randomized, double-blind, placebo-controlled trial, 1,649 individuals with mild Alzheimer's (mean MMSE in both groups = 23.3) were randomized 1:1 to receive tarenflurbil 800 mg twice-a-day or placebo for 18 months. The co-primary outcome measures of efficacy were two standard measures of cognition and the ability to accomplish activities of daily living, respectively the ADAS-cog and the ADCS-ADL, with assessments conducted every three months. The secondary outcome measure was the Clinical Dementia Rating scale. Exploratory outcomes included the Neuropsychiatric Inventory (NPI), Quality of Life-Alzheimer's test, and Caregiver Burden Inventory.

The researchers found that the drug did not achieve statistical significance in either of its primary endpoints of cognition and activities of daily living. Also, it did not achieve statistical significance on the secondary endpoint. By the end of the 18-month trial, patients in both the tarenflurbil and placebo groups had declined approximately seven points on the ADAS-cog scale and 10 points on the ADCS-ADL scale.

According to the researchers, the reported adverse effects reflect the expected profile of the elderly population with Alzheimer's and, in most participants, symptoms were well balanced between the tarenflurbil and placebo groups. However, in the tarenflurbil treatment group, there was increased frequency of anemia (9.7 percent vs. 4.5 percent), infections (pneumonia, H. zoster, sepsis) (6.9 percent vs. 2.9 percent), and gastrointestinal ulcers (1.7 percent vs. 0.4 percent).

"This was the larg
'/>"/>

SOURCE Alzheimer's Association
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
2. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
4. Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation
5. Controversy About Lack of Placebo Group Decline in Alzheimers Clinical Trials
6. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
7. Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer
8. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
9. Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
10. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
11. Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PITTSBURGH , July 30, 2014   ... Markets Groups Inc.: OTC Pink: UPZS), a Delaware ... a distribution agreement with Larasan Pharmaceutical Corporation ("Larasan"), a ... products.  According to the agreement, US-based Larasan will ... gourmet 6" frozen pizza through Larasan,s vast distribution ...
(Date:7/30/2014)... KISSING, Germany , July 30, 2014 ... single use and computer-assisted ("robotic") colonoscopy system, today announced ... worldwide recognized medical device executive, as a new member ... is a highly respected global visionary in the medical ... as President and Chief Executive Officer at Given Imaging ...
(Date:7/30/2014)... and PARIS , July 30, ... ) and Sanofi (EURONEXT: SAN and NYSE: ... ODYSSEY trials of alirocumab in people with hypercholesterolemia met ... from baseline in low-density lipoprotein cholesterol (LDL-C) at 24 ... an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin ...
Breaking Medicine Technology:Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 3invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8
... 2011 Thoratec Corporation (NASDAQ: THOR ... support therapies to save, support and restore failing ... WiTricity Corporation relating to WiTricity,s proprietary wireless resonant ... of mechanical circulatory support. Through a ...
... Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) today ... 2011, and reviewed recent developments. "In collaboration ... support the submission of our response to the FDA,s complete ... Lief, Arena,s President and Chief Executive Officer. "We are also ...
Cached Medicine Technology:Thoratec Announces Development Agreement With WiTricity for Proprietary Energy Transfer Technology 2Thoratec Announces Development Agreement With WiTricity for Proprietary Energy Transfer Technology 3Thoratec Announces Development Agreement With WiTricity for Proprietary Energy Transfer Technology 4Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments 2Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments 3Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments 4Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments 5Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments 6Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments 7Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments 8
(Date:7/30/2014)... ... ... ... , UCLA researchers interviewed ... study, published this week in the peer-reviewed journal Quality of Life Research , a UCLA team led by Dr. Brennan Spiegel ...
(Date:7/30/2014)... 2014 The Ehlers-Danlos National Foundation (EDNF) ... Sandra Aiken Chack will serve as chair. The board ... 2014 Annual Learning Conference in Houston, Texas July 10-12. ... agenda ahead of us. From the rollout of the ... the Greater Baltimore Medical Center to our September physicians ...
(Date:7/30/2014)... LTC Consumer, an independent, free online service to help consumers ... Quote tool on its website, LTCconsumer.com , announced Nathan ... free and unlimited. , The Instant Quote tool ... age, gender, and state of residence – and delivers a ... enter any contact information to get started). There is no ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 The ... to U.S. Sens. Thad Cochran (R-MS) and Roger ... improvements in telemedicine coverage under Medicare, Medicaid and ... Wicker, both Mississippi Republicans, introduced the Telehealth Enhancement ... a House version, H.R. 3306, introduced by Rep. ...
(Date:7/30/2014)... 2014 Hospitals continually face the ... care that their practitioners provide. During a recent ... discussed the importance of establishing effective peer review ... and quality of care. , With regard ... Rowe elaborated on setting performance expectations, conducting regular ...
Breaking Medicine News(10 mins):Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 3Health News:Ehlers-Danlos National Foundation Announces New Leadership 2Health News:LTC Consumer Launches Online Tool for Getting Instant Long Term Care Insurance Estimates 2Health News:ATA Applauds Senators’ Push for Federal Telemedicine Improvements 2Health News:AllMed Webinar Helps Hospitals Optimize Practitioner Evaluations in Peer Review 2Health News:AllMed Webinar Helps Hospitals Optimize Practitioner Evaluations in Peer Review 3
... , WOODLAND HILLS, Calif., Sept. 22 ... the California Governor,s Council on Physical Fitness and Sports, is ... moving and empower them to make healthy lifestyle choices now ... view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/livelikeachampion/40152/ ...
... , , RICHMOND, Va., Sept. 22 ... Richmond Health System has been named among the Top Ten 2009 ... benefits. Bon Secours Richmond has been named to Working Mother ,s ... Ten in both 2006 and 2009. , , "Being ...
... ... launch of two newly redesigned websites, R&D ( http://www.rdmag.com ) and Wireless Week ( ... to foster an online community for their users. , ... Rockaway, New Jersey (PRWEB) September 22, 2009 -- ...
... , DUQUESNE, Pa., Sept. 22 Wherever you ... the house. From pulling out blankets, replacing smoke detector batteries, varying ... "flipping" their home routines in the fall. , ... , If you are one of the estimated ...
... IBI Lost Productivity Calculators based on research with ... Sept. 22 To enable employers to estimate the productivity ... created three proprietary, on-line Lost Productivity Calculators for its members. ... company, a specific occupation group, or a specific group of ...
... Oncology (ESMO) has recognized the outstanding achievements of three ... the 2009 ESMO Award, Hamilton Fairley Award and ESMO ... Lead for Medical Oncology, Institute of Cancer, Barts and ... the 2009 Hamilton Fairley Award. The award commemorates one ...
Cached Medicine News:Health News:Video: Anthem Blue Cross and the California Governor's Council on Physical Fitness and Sports Launch the Live Like a Champion Tour 2Health News:Video: Anthem Blue Cross and the California Governor's Council on Physical Fitness and Sports Launch the Live Like a Champion Tour 3Health News:Bon Secours Richmond Named A Top Ten 2009 Working Mother 100 Best Company 2Health News:Bon Secours Richmond Named A Top Ten 2009 Working Mother 100 Best Company 3Health News:Bon Secours Richmond Named A Top Ten 2009 Working Mother 100 Best Company 4Health News:Advantage Business Media Launches Enhanced Websites 2Health News:Advantage Business Media Launches Enhanced Websites 3Health News:'Flip for Fall' Seasonal Household Tips Include Ten Million Reasons to Use Allergy-Protective Bedding 2Health News:'Flip for Fall' Seasonal Household Tips Include Ten Million Reasons to Use Allergy-Protective Bedding 3Health News:Integrated Benefits Institute Launches Productivity Modeling Tools to Help Employers Estimate the Impact of Absent Employees 2Health News:ESMO recognizes leading oncologists with prestigious awards 2Health News:ESMO recognizes leading oncologists with prestigious awards 3
... F340 is a basic laboratory system for ... results can be obtained when used with ... electrode. • Fast and easy one and ... for five buffers (pH 1.68, 4.00, 7.00, ...
... the multifunctional high-end microplate reader with outstanding ... modes., Fluorescence Intensity - FRET , ... HTRF, AlphaScreen , Luminescence , ... emission microplate reader with fastest read times. ...
... microplate reader combines improved flexibility ... with a wide range of ... the flexibility, sensitivity and high ... is the ideal detection solution ...
... for Ultra High Throughput Screening (UHTS), ... detection performance. Allows for smooth transfer ... development by sharing all the detection ... fluorescence intensity, fluorescence polarization, time-resolved fluorescence, ...
Medicine Products: